Genomic Vision discloses new corporate governance with Florence Allouche as Chair of the Supervisory Board

– FRANCE, Bagneux –  Genomic Vision (EPA: GV), a biotechnology company, today announced the appointments of Florence Allouche, Dr. Mohammad Afshar (Ph.D.), and Eric Edery to its Supervisory Board as Independent Directors.

Concurrently, the company announced the revocations of Elisabeth Ourliac, Tammou Abikhzer, and Stéphane Verdood from the Supervisory Board, and Dominique Remy-Renou from the Executive Board.

Consequently, the company announced the appointments of Dr. Aaron Bensimon (Ph.D.) as Chair of the Executive Board and Florence Allouche as Chair of the Supervisory Board.

“It gives me great pleasure to be the new Chair of Genomic Vision’s Supervisory Board. Eric, Mohammad, and I will combine our complementary fields of expertise and experience and use them to advance Genomic Vision’s ambitious strategy,” said Supervisory Board Chir, Florence Allouche.

Aaron Bensimon added: “The appointment of a new Supervisory Board with highly qualified members who are international experts in our industry is a strong step forward for the Company and our ambitions. I would like to thank Florence, Eric, and Mohammad for their commitment and their enthusiasm. Moreover, I am very pleased to welcome Emilie and Lionel to their new positions, both bringing a fresh and independent perspective to Genomic Vision.”

About Dr. Aaron Bensimon, Chair of the Executive Board

Doctor of Molecular Biology, he founded Genomic Vision in 2004, before being appointed CEO of the Company in May 2006. He is also the Company’s Scientific Director.
Throughout his tenure, Dr. Bensimon forged several partnerships with key players in the pharma and biotech sector including with Quest Diagnostics, Editas Medicine, Sanofi Aventis, and AstraZeneca, amongst others, and successfully led the Company’s IPO on Euronext in 2014.
Dr. Aaron Bensimon jointly discovered the DNA “molecular combing” process. With unique expertise in this technology and its applications in molecular diagnostics, he has made a significant contribution to the development of this discipline and has published numerous articles in prestigious scientific journals (Science, Nature, Cell, etc.)
He is the author of more than 20 patent filings concerning molecular combing.
Before founding Genomic Vision, he spent 15 years as a researcher at the Pasteur Institute in Paris where, from 1994, he headed the Genome Stability Unit. It was during his research in collaboration with the Ecole Normale Supérieure Paris’ statistical physics laboratory that he discovered the DNA molecular combing process.
In 1995, he received the Jacques Monod award from the Fondation de France, which recognizes young researchers who have made significant breakthroughs at the beginning of their careers.
From 1992 to 1993, he worked in Prof. Jean-Pierre Changeux’s laboratory (Pasteur Institute, Paris). His research focused on studying the myogenin gene’s involvement in muscle denervation. This project was financed by the prestigious “Human Frontier Science Program” grant obtained after earning his doctorate at the Weizmann Institute in Israel.
Aaron Bensimon has also followed the prestigious HEC business school’s “Challenges+” management training and regularly speaks at scientific conferences.

About Florence Allouche, Chair of the Supervisory Board:

PharmD – Paris University, MBA – HEC Paris, Board Director certified – IFA/Sciences Po Paris. A biologist at AP-HP (Greater Paris Hospitals), Florence has held several positions within the diagnostics industry.
She created and spent 16 years running the AP-HP Tech Transfer Office. 1,000 patent families filed, 300 licensing agreements signed, €25 million in annual revenue, and 75 startups created. Expert & mentor for the main Paris incubators, she represented the French technology transfer at the international level (AUTM, ASTP).
In 2016, Florence Allouche cofounded and was CEO of SparingVision, a genomic medicines company, transforming 20 years of state-of-the-art ophthalmic research at the Paris Vision Institute into sight-saving treatments for retinitis pigmentosa, moving beyond single gene correction therapies to gene-independent treatments. SparingVision raised €60 million in series A and recently €75 million in series B and obtained several grants.
Florence Allouche is a Professor at Paris Cité University’s Faculty of Pharmacy, specializing in pharmaceutical innovation and entrepreneurship. She is the founder and President of Myrpharm Advisors, a consulting firm helping translational academic research through startup creation, tech transfer, business development, innovation management, funding, strategy, growth, and mentoring.
(Member of the French National Academy of Pharmacy, Member of the EIT Health Venture Center of Excellence Scientific Advisory Board, Prev. Member of the supervisory board of the Big Investment Plan oversight committee under the authority of the French Prime Minister (SGI), First Prize Biotech in the CATAPULT 2019 European Startups Competition, Finalist in the Prix Galien International, New York (US) – Med’Startup, 2019, Mercure Entrepreneurs award – HEC Paris 2019, Women’s Trajectory award – HEC Paris 2018, Named “Woman of the Year 2017” by French financial magazine “La Tribune”.)

About Eric Edery

Eric J.Edery is a financial advisor and Venture Capital fund partner.
After graduating in Finance from the Sorbonne, Eric spent 10 years working at Morgan Stanley Dean Witter in Paris on a Sovereign Debt desk and in an Equity Sales department before joining the Private Wealth division in Zurich. Since 2016, he has been advising Tech and Biotech companies across Europe. He is on the Advisory Board of WebInfluence Group, an Adtech company.

Dr. Mohammad Afshar

Mohammad Afshar is the founder and CEO of Ariana Pharma, a drug development company based in Paris (France) and Boston (USA) specializing in Artificial Intelligence (AI). Ariana Pharma specializes in precision medicine clinical trials, transforming multi-omic data into innovative clinical development plans and regulatory approvals.
Before joining Ariana Pharma, Mohammad Afshar was the founder and Director of Drug Design at RiboTargets, Cambridge, UK. He set up and managed the platform that discovered and successfully patented several novel therapeutic molecules. Before joining RiboTargets, he held several academic positions, notably in York University’s Chemistry Department in the UK and the CNRS’ CRBM research institute in France. He holds a Medical Degree (DCEM), a master’s in computer science (DEA), a Ph.D. in structural biochemistry, and a Ph.D. HDR (enabling him to lead research projects) from Montpellier University’s Faculty of Medicine in France. Since 2014, he has been on the Seventure Partners VC fund’s investment advisory board.

About Genomic Vision

Genomic Vision is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed for the highly confident characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cfor ancerous cells, for early cancer detection, and the diagnosis of genetic diseases. Genomic Vision, based near Paris in Bagneux, is a publicly listed company listed in compartment C of Euronext’s regulated market in Paris.

For more information,

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.